Approval of Esketamine for Treatment-Resistant Depression – Author's Reply

The Lancet Psychiatry - United Kingdom
doi 10.1016/s2215-0366(20)30044-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Approval of Esketamine for Treatment-Resistant Depression – Authors' Reply

The Lancet Psychiatry
PsychiatryBiological PsychiatryMental Health
2020English

Approval of Esketamine for Treatment-Resistant Depression

The Lancet Psychiatry
PsychiatryBiological PsychiatryMental Health
2020English

156 Improvement in Disease Severity in Patients With Treatment-Resistant Depression Following Treatment With Intranasal Esketamine

CNS Spectrums
PsychiatryMental HealthNeurology
2018English

Tako Tsubo and Treatment of Comorbid Depression: A Reflection Is Needed - Author's Reply

Clinical Practice and Epidemiology in Mental Health
PsychiatryEpidemiologyMental Health
2019English

Treatment of Hypercalcaemia of Malignancy: Author's Reply

BMJ
1988English

Cefiderocol for Treatment of Complicated Urinary Tract Infections – Author's Reply

The Lancet Infectious Diseases
Infectious Diseases
2019English

Depression and Outcome in Acute Myocardial Infarction:: Author's Reply

BMJ
1987English

Author's Reply

Journal of Cardiology
Cardiovascular MedicineCardiology
2016English

Author's Reply

BJPsych Bulletin
PsychiatryMental Health
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy